aTyr Pharma
ATYR
24 hedge funds and large institutions have $24.9M invested in aTyr Pharma in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
633% more capital inflows, than outflows
Capital inflows: $1.54M | Capital outflows: $210K
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
3.76% more ownership
Funds ownership: 56.1% → 59.86% (+3.8%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$569K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$247K |
| 3 |
Two Sigma Investments
New York
|
+$246K |
| 4 |
Two Sigma Advisers
New York
|
+$162K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$62K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$44.6K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$24K |
ATYR Hedge Fund Activity: Q2 2020 in Review
24 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2020, worth a combined $24.9M — up 69% from $14.7M a quarter earlier.
Fund positioning in ATYR was balanced in Q2 2020: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $569K. The largest seller was Millennium Management, exiting entirely with an estimated $62K sold.
- 24 institutional investors held aTyr Pharma (ATYR) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $24.9M of aTyr Pharma stock for Q2 2020, up 69% quarter-over-quarter.
- 4 funds opened new aTyr Pharma positions in Q2 2020 and 4 closed out, a net change of 0 holders.
- The largest aTyr Pharma buyer in Q2 2020 was Renaissance Technologies, an estimated $569K added.
- The largest aTyr Pharma seller in Q2 2020 was Millennium Management, an estimated $62K sold.
Based on aggregated 13F filings for Q2 2020.